Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + motesanib + paclitaxel + panitumumab
- Development stage
- Phase 2
- Lead developer
- Johnson Matthey
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of carboplatin (a platinum-based chemotherapy agent), motesanib (a small-molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and Kit), paclitaxel (a taxane chemotherapy agent), and panitumumab (a fully human anti-epidermal growth factor receptor monoclonal antibody). This combination has been investigated in clinical trials for advanced non-small cell lung cancer (NSCLC).
02
Targets
DNAEGFR (Epidermal growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MicrotubulePDGFR (PDGFR family)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carboplatin + motesanib + paclitaxel + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + motesanib + paclitaxel + panitumumab.